People with type 2 diabetes who take GLP-1 and SGLT-2 medications have a lower risk of having COPD symptom flare-ups than ...

A new study suggests that medications that have transformed the treatment of obesity may also help people drink less alcohol.

In today’s fast-paced world, many individuals struggle with weight management, feeling overwhelmed by conflicting advice and ...

Millions of Americans use GLP-1 injections like Ozempic to lose weight. A study is questioning whether they can cause vision loss.

Independence Blue Cross began limiting coverage of GLP-1 drugs on Jan. 1 to some medical conditions, but not obesity or weight loss.

The data, published in JAMA Psychiatry, add to the growing body of evidence supporting the use of GLP-1 receptor agonists for ...

The next FDA Commissioner could solve two big problems with one powerful policy: encourage independent testing of both ...

Novo Nordisk shares dropped due to CagriSema trial results but have long-term upside. Learn why NVO stock is a Strong Buy ...

The potential market for the drugs is massive — more than 40 percent of adults in the U.S. are obese — and has seen explosive growth. The number of Americans taking GLP-1s for weight loss rose more ...

Most economists expect muted U.S. economic growth in the coming quarters, and some indicators suggest a mild U.S. recession is still a possibility. It may become difficult for investors to ...

Obesity is an epidemic in the United States, but more people are shedding pounds with the help of weight loss drugs.

From revenue to R&D investment, Novo and Lilly and their mega-blockbuster weight loss drugs Zepbound and Wegovy have moved ...